Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038098 · ClinicalTrials.gov registry record · Phase 1
Magnetic Sentinel Lymph Node Mapping in Gastric Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05038098: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT05038098 is a Phase 1 study that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05038098, a Phase 1 study, has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help researchers better detect the disease.
Interventions
- DRUG Indocyanine Green
- PROCEDURE Gastrectomy
- OTHER Iron Conjugated Polymers in Saline Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-31 |
| Est. Completion | 2027-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05038098
The ClinicalTrials.gov registry entry for NCT05038098 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Indocyanine Green is the first listed.
NCT05038098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05038098 about?
NCT05038098 is a clinical study titled "Magnetic Sentinel Lymph Node Mapping in Gastric Cancer". This phase I finds out the possible benefits and/or side effects of using magnetic tracer FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer is most likely to have spread to in patients with gastric cancer that are undergoing gastrectomy. Using FerroTrace in...
What is the current status of trial NCT05038098?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-03-31. Estimated completion is 2027-02-02.
What interventions are being tested in trial NCT05038098?
The interventions under investigation include: Indocyanine Green (DRUG), Gastrectomy (PROCEDURE), Iron Conjugated Polymers in Saline Suspension (OTHER).
Who is sponsoring clinical trial NCT05038098?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.